|
Age by 10 years
|
TAVR vs MM
|
TAVR vs SAVR
|
TAVR vs MM
|
TAVR vs SAVR
|
TAVR vs MM
|
TAVR vs SAVR
|
|
Non-white race
|
1.01 (1.01–1.01)
|
1.00 (1.00–1.01)
|
−43.90 (−47.04- -40.76)
|
−3.66 (− 192.18–184.84)
|
− 0.02 (− 0.02- -0.02)
|
−0.06 (− 0.07- -0.05)
|
|
Zip code income
|
1.03 (1.02–1.04)
|
0.98 (0.78–1.23)
|
3953.27 (3833.21-4073.34)
|
31,486.94 (25,653.33-37,320.55)
|
0.31 (0.30–0.32)
|
1.12 (0.84–1.40)
|
|
1st quartile
|
Reference
|
Reference
|
Reference
|
Reference
|
Reference
|
Reference
|
|
2nd quartile
|
0.96 (0.95–0.98)
|
0.91 (0.71–1.16)
|
2120.83 (1976.57-2265.09)
|
4416.36 (− 1564.70-10,397.41)
|
− 0.13 (− 0.15- -0.12)
|
−0.20 (− 0.49–0.09)
|
|
3rd quartile
|
0.92 (0.90–0.93)
|
0.98 (0.77–1.25)
|
5372.67 (5224.71-5520.64)
|
16,506.95 (10,558.02-22,455.89)
|
−0.17 (− 0.18- -0.16)
|
−0.49 (− 0.78- -0.20)
|
|
4th quartile
|
0.93 (0.91–0.95)
|
0.92 (0.71–1.19)
|
9909.08 (9751.90-10,066.26)
|
31,220.53 (25,154.54-37,246.52)
|
−0.11 (− 0.12- -0.09)
|
−0.25 (− 0.54–0.04)
|
|
Procedure
|
0.52 (0.43–0.63)
|
0.90 (0.70–1.16)
|
164,413 (162,704.90-166,121.10)
|
52,098.41 (46,359.88-57,836.93)
|
−0.01 (− 0.17–0.14)
|
− 3.85 (− 4.13- -3.58)
|
|
Malignancy
|
1.08 (1.06–1.10)
|
1.07 (0.78–1.47)
|
2606.99 (2441.96-2772.02)
|
− 7911.60 (− 15,835.76–12.55)
|
0.06 (0.05–0.08)
|
− 0.89 (− 1.27- -0.51)
|
|
Metastases
|
1.95 (1.91–2.00)
|
0.63 (0.15–2.70)
|
− 6706.27 (− 7033.93- -6378.60)
|
922.71 (− 575.25–22,025.82)
|
− 0.31 (− 0.34- -0.28)
|
0.86 (− 0.81–2.54)
|
|
With Procedure
|
0.71 (0.45–1.11)
|
0.76 (0.43–1.32)
|
−5186.04 (− 8627.01- -1745.08)
|
10,725.28 (− 575.25–22,025.82)
|
− 0.72 (− 1.04- -0.40)
|
0.35 (− 0.20–0.89)
|
|
Mortality risk by DRG
|
7.88 (7.81–7.96)
|
10.74 (8.93–12.93)
|
8108.62 (8042.55-8174.68)
|
21,602.97 (18,898.19-24,307.74)
|
2.10 (2.09–2.10)
|
4.29 (4.18–4.41)
|
|
Length of stay, days
| | |
7514.37 (7505.36-7523.38)
|
14,544.34 (14,262.47-14,826.21)
| | |
